Tfelt-Hansen P, Saxena P R, Dahlöf C, Pascual J, Láinez M, Henry P, Diener H, Schoenen J, Ferrari M D, Goadsby P J
Department of Neurology, Glostrup Hospital, Copenhagen, Denmark. The
Brain. 2000 Jan;123 ( Pt 1):9-18. doi: 10.1093/brain/123.1.9.
Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice. An expert group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of migraine. From this review, specific suggestions for the patient groups and appropriate use of ergotamine have been agreed. In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions. For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective.
麦角胺已在临床实践中用于偏头痛的急性治疗达50多年,但对于其在临床实践中的地位一直存在很少的共识。一个来自欧洲的专家小组回顾了与偏头痛治疗相关的麦角胺的临床前和临床数据。通过这次回顾,已就针对患者群体的具体建议以及麦角胺的适当使用达成了一致。从本质上讲,从医学角度来看,麦角胺是少数患有不频繁或持续时间长的头痛且可能遵守给药限制的偏头痛患者的首选药物。对于大多数需要特定抗偏头痛治疗的偏头痛患者,从疗效和副作用角度来看,曲坦类药物通常是更好的选择。